Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + tislelizumab neoadjuvant therapy in platinum-ineligible locally advanced HNSCC
ChiCTR2600116769Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nimotuzumab and tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective response rate after neoadjuvant therapy. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
nimotuzumabtislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600116769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116769.